Sickle cell disease and H3Africa: Enhancing genomic research on cardiovascular diseases in African patients

Cardiovascular Journal of Africa

Volumn 26, Issue 2, 2015, Pages S50-S55

  Wonkam, Ambroise ^a   Makani, Julie ^b   Ofori Aquah, Solomon ^c   Nnodu, Obiageli E ^d   Treadwell, Marsha ^e   Royal, Charmaine ^f   Ohene Frempong, Kwaku ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF ABUJA   (Nigeria)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Africa; Genetics; Kidney diseases; Pulmonary hypertension; Sickle cell disease; Stroke

Indexed keywords

HEMOGLOBIN F;

AFRICAN; ALPHA THALASSEMIA; ARTICLE; CAMEROON; CARDIOVASCULAR DISEASE; CHILDHOOD MORTALITY; GENE LOCUS; GENOMICS; HUMAN; INHERITANCE; MEDICAL RESEARCH; SCREENING; SICKLE CELL ANEMIA; SURVIVAL; TANZANIA; AFRICA; ANEMIA, SICKLE CELL; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PREVALENCE; RESEARCH;

AFRICA; ANEMIA, SICKLE CELL; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PREVALENCE; RESEARCH;

EID: 84930020319     PISSN: 19951892     EISSN: 16800745     Source Type: Journal    
DOI: 10.5830/CVJA-2015-040     Document Type: Article

References (64)

1. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381(9861): 142-151.
2. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74(2): 652-656.
3. Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr 2009; 154(4): 541-545.
4. Rahimy MC, Gangbo A, Ahouignan G, et al. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood 2003; 102(3): 834-838.
5. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol 1991; 28(3): 220-226.
6. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med 2013; 10(7): e1001484.
7. Makani J, Cox SE, Soka D, et al. Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One 2011; 6(2): e14699.
8. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008; 105(33): 11869-11874.
9. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009; 145(4): 455-467.
10. Bae HT, Baldwin CT, Sebastiani P, et al. Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood 2012; 120(9): 1961-1962.
11. Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 2011; 334(6058): 993-996.
12. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013; 342(6155): 253-257.
13. Makani J, Menzel S, Nkya S, et al. Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood 2011; 117(4): 1390-1392.
14. Wonkam A, Ngo Bitoungui VJ, Vorster AA, et al. Association of variants at BCL11A and HBS1L-MYB with hemoglobin F and hospitalization rates among sickle cell patients in Cameroon. PLoS One 2014; 9(3): e92506.
15. Bitoungui VJ, Ngogang J, Wonkam A. Polymorphism at BCL11A compared to HBS1L-MYB loci explains less of the variance in HbF in patients with sickle cell disease in Cameroon. Blood Cells Mol Dis 2014 Nov 25. pii: S1079-9796(14)00143-0.
16. Menzel S, Rooks H, Zelenika D, et al. Global Genetic Architecture of an Erythroid Quantitative Trait Locus, HMIP-2. Ann Hum Genet 2014 Jul 29. doi: 10.1111/ahg.12077.
17. Ngo Bitoungui VJ, Pule GD, Hanchard N, Ngogang J, Wonkam A. Beta-globin gene haplotypes among Cameroonians and review of the global distribution: is there a case for a single sickle mutation origin in Africa? OMICS J Integrat Biol 2015; 19(3): DOI: 10.1089/omi.2014.0134.
18. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood 2010; 115(9): 1815-1822.
19. Mtatiro SN, Singh T, Rooks H, et al. Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania. PLoS One 2014; 9(11): e111464.
20. Hsu LL, Miller ST, Wright E, et al. Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 2003; 25(8): 622-628.
21. Embury SH, Dozy AM, Miller J, et al. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 1982; 306(5): 270-274.
22. Wonkam A, Rumaney MB, Ngo Bitoungui VJ, et al. Coinheritance of sickle cell anemia and α-thalassemia delays disease onset and could improve survival in Cameroonian's patients (Sub-Saharan Africa). Am J Hematol 2014; 89(6): 664-665.
23. Rumaney MB, Ngo Bitoungui VJ, Vorster AA, et al. The co-inheritance of alpha-thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS One 2014; 9(6): e100516.
24. Cox SE, Makani J, Soka D, et al. Haptoglobin, alpha-thalassaemia and glucose-6-phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania. Br J Haematol 2014; 165(5): 699-706.
25. Flanagan JM, Sheehan V, Linder H, et al. Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood 2013; 121(16): 3237-3245.
26. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91(1): 288-294.
27. Njamnshi AK, Mbong EN, Wonkam A, et al. The epidemiology of stroke in sickle cell patients in Yaounde, Cameroon. J Neurol Sci 2006; 250(1-2): 79-84.
28. Njamnshi AK, Wonkam A, Djientcheu Vde P, et al. Stroke may appear to be rare in Saudi Arabian and Nigerian children with sickle cell disease, but not in Cameroonian sickle cell patients. Br J Haematol 2006; 133(2): 210.
29. Aliyu ZY, Gordeuk V, Sachdev V, et al. Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol 2008; 83(6): 485-490.
30. DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012; 119(20): 4587-4596.
31. Ruffieux N, Njamnshi AK, Wonkam A, et al. Association between biological markers of sickle cell disease and cognitive functioning amongst Cameroonian children. Child Neuropsychol 2013; 19(2): 143-160.
32. Lagunju I, Sodeinde O, Telfer P. Prevalence of transcranial Doppler abnormalities in Nigerian children with sickle cell disease. Am J Hematol 2012; 87(5): 544-547.
33. Makani J, Kirkham FJ, Komba A, et al. Risk factors for high cerebral blood flow velocity and death in Kenyan children with sickle cell anaemia: role of haemoglobin oxygen saturation and febrile illness. Br J Haematol 2009; 145(4): 529-532.
34. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895.
35. Aliyu ZY, Kato GJ, Taylor J 6th, et al. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol 2008; 83(1): 63-70.
36. Aliyu ZY, Suleiman A, Attah E, et al. NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. Br J Haematol 2010; 150(1): 102-107.
37. Cox SE, Soka D, Kirkham FJ, et al. Tricuspid regurgitant jet velocity and hospitalization in Tanzanian children with sickle cell anemia. Haematologica 2014; 99(1): e1-4.
38. Arlet JB, Ribeil JA, Chatellier G, et al. Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: a prospective observational cohort study. BMC Nephrol 2012; 13: 83.
39. Iwalokun BA, Iwalokun SO, Hodonu SO, Aina OA, Agomo PU. Evaluation of microalbuminuria in relation to asymptomatic bacteruria in Nigerian patients with sickle cell anemia. Saudi J Kidney Dis Transpl 2012; 23(6): 1320-1330.
40. Adedoyin OT, Adesiyun OO, Adegboye OA, Bello OA, Fatoye OP. Sickle cell nephropathy in children seen in an African hospital - case report. Niger Postgrad Med J 2012; 19(2): 119-122.
41. Osei-Yeboah CT, Rodrigues O. Renal status of children with sickle cell disease in Accra, Ghana. Ghana Med J 2011; 45(4): 155-160.
42. Pakasa NM, Sumaïli EK. [Pathological peculiarities of chronic kidney disease in patient from sub-Saharan Africa. Review of data from the Democratic Republic of the Congo]. Ann Pathol 2012; 32(1): 40-52.
43. Driscoll MC, Hurlet A, Styles L, et al. Stroke risk in siblings with sickle cell anemia. Blood 2003; 101(6): 2401-2404.
44. Kwiatkowski JL, Hunter JV, Smith-Whitley K, Katz ML, Shults J, Ohene-Frempong K. Transcranial Doppler ultrasonography in siblings with sickle cell disease. Br J Haematol 2003; 121(6): 932-937.
45. Flanagan JM, Frohlich DM, Howard TA, et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 2011; 117(24): 6681-6684.
46. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330(23): 1639-1644.
47. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329(5993): 841-845.
48. Ashley-Koch AE, Okocha EC, Garrett ME, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155(3): 386-394.
49. Desai AA, Zhou T, Ahmad H, et al. A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease. Am J Respir Crit Care Med 2012; 186(4): 359-368.
50. Elira Dokekias A, Okandze Elenga JP, Ndinga J, Sanogo I, Sangare A. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia]. Tunis Med 2005; 83(1): 32-7.
51. Mellouli F, Bejaoui M. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases]. Arch Pediatr 2008; 15(1): 24-28.
52. Wonkam A, Ponde C, Nicholson N, Fieggen K, Ramessar R, Davidson A. The burden of sickle cell disease in Cape Town. S Afr Med J 2012; 102(9): 752-754.
53. Makubi A, Soka D, Makani J. Moyamoya disease, a rare cause of recurrent strokes in an african sickle cell child: does hydroxyurea have a role in this context? Int J Child Health Nutr 2012; 1: 82-85.
54. Ware RE. Hydroxycarbamide: clinical aspects. Comptes Rendus Biol 2013; 336(3): 177-182.
55. Olabode JO, Shokunbi WA. Types of crises in sickle cell disease patients presenting at the haematology day care unit (HDCU), University College Hospital (UCH), Ibadan. West Afr J Med 2006; 25(4): 284-288.
56. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997; 89(3): 1078-1088.
57. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377(9778): 1663-1672.
58. Wonkam A, Mba CZ, Mbanya D, et al. Psychosocial burden of sickle cell disease on parents with an affected child in Cameroon. J Genet Couns 2014; 23(2): 192-201.
59. H3Africa Consortium. Research capacity. Enabling the genomic revolution in Africa. Science 2014; 344(6190): 1346-1348.
60. Peprah E, Xu H, Tekola-Ayele F, Royal CD. Genome-wide association studies in Africans and African Americans: Expanding the framework of the genomics of human traits and disease. Public Health Genom 2015; 18(1): 40-51.
61. Lambert CA, Tishkoff SA. Genetic structure in African populations: implications for human demographic history. Cold Spring Harb Symp Quant Biol 2009; 74: 395-402.
62. Gurdasani D, Carstensen T, Tekola-Ayele F, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature 2015; 517(7534): 327-332.
63. Kappler-Gratias S, Auxerre C, Dubeaux I, et al. Systematic RH genotyping and variant identification in French donors of African origin. Blood Transfus 2014; 12(Suppl 1): s264-272.
64. Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol 2014; 10(6): 769-785.